182886-84-6

Upstream product

• 105-36-2 ethyl bromoacetate 
• 182886-83-5 (S)-hexahydro-7,7-dimethyl-3-<(triphenylmethyl)amino>-2H-azepin-2-one 
• 182886-39-1 (S)-hexahydro-6-phthalimido-2,2-dimethyl-2H-azepin-7-one 
• 197902-93-5 (S)-2-phthalimido-6-methyl-6-azidoheptanoic acid, phenylmethyl ester 
• 197902-92-4 (S)-2-phthalimido-6-methyl-6-hydroxyheptanoic acid, phenylmethyl ester 
• 182886-36-8 (S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-6-oxo-heptanoic acid benzyl ester 
• 197902-91-3 (2S)-2-phthalimido-6-hydroxyheptanoic acid, phenylmethyl ester 
• 84688-14-2 benzyl (S)-2-(1,3-dioxoisoindolin-2-yl)-6-oxohexanoate 
• 84688-11-9 (S)-2-(1,3-dioxoisoindolin-2-yl)-6-hydroxyhexanoic acid 

Downstream Products

• 160135-15-9 [S-(R*,R*)]-Hexahydro-6-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid, ethyl ester 
• 160135-92-2 [14C]-Gemopatrilat 

Relevant academic research and scientific papers

Vasopeptidase inhibitors: Incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides

A series of 7-(di)alkyl and spirocyclic substituted azepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipeptides. Clear structure-activity relationships with respect to both angiotensin-converti

SUBSTITUTED AZEPINONE DUAL INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL EXDOPEPTIDASE

Compounds of the formula STR1 are disclosed as possessing inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents. Processes for preparing these compounds are also disclosed.